VIA
PHAT icon

Virtus Investment Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

Virtus Investment Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
112,139
+54,153
+93% +$618K 0.28% 176
2026
Q1 		$644K Buy
57,986
+11,049
+24% +$140K 0.18% 187
2025
Q4 		$779K Buy
46,937
+2,631
+6% +$37.6K 0.21% 145
2025
Q3 		$521K Hold
44,306
– – 0.15% 201
2025
Q2 		$425K Sell
44,306
-658
-1% -$3.64K 0.14% 217
2025
Q1 		$282K Buy
+44,964
New +$273K 0.08% 245

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Virtus Investment Advisers's PHAT Position: Q2 2026 in Review

Virtus Investment Advisers increased its Phathom Pharmaceuticals (PHAT) stake by 93% in Q2 2026, buying an estimated $618K and bringing the position to 112,139 shares worth $1.22M. The position accounts for 0.28% of the portfolio, ranked #176.

Virtus Investment Advisers first reported a position in PHAT in Q1 2025 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Virtus Investment Advisers held 112,139 shares of Phathom Pharmaceuticals worth $1.22M as of Q2 2026.
  • Virtus Investment Advisers bought 54,153 Phathom Pharmaceuticals shares in Q2 2026, an estimated $618K.
  • Phathom Pharmaceuticals made up 0.28% of Virtus Investment Advisers's portfolio in Q2 2026, its #176 holding.
  • Virtus Investment Advisers first reported a position in Phathom Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.